

| | | | | | | | |
|--|--|--|--|--------------------------|--|-------------|--|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | | | |
| | | | | Application Number | | | |
| | | | | Filing Date | | | |
| | | | | First Named Inventor | | | |
| | | | | Group Art Unit | | | |
| | | | | David WALLACH | | | |
| | | | | 1642 | | | |
| | | | | Examiner Name | | | |
| Sheet | | | | of | | 2 | |
| | | | | Attorney Docket Number | | WALLACH=16A | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | AI | ITO et al, "A novel protein domain required for apoptosis", <u>J. Biol. Chem.</u> 268(15):10932-10937 (1993) | |
| | AJ | NAGATA et al, "Fas and Fas ligand: A death factor and its receptor", <u>Advances in Immunology</u> 57:129-144 (1994) | |
| | AK | SONG et al, "Aggregation of the Intracellular Domain of the Type 1 Tumor Necrosis Receptor Defined by the Two-hybrid System", <u>J. Biol. Chem.</u> 269(36):22492-22495 (1994) | |
| | AL | GenBank Accession No. Q15121: "Astrocytic phosphoprotein", November 1, 1997 | |
| | AM | GenBank Accession No. X86809: "H. sapiens mRNA for major astrocytic phosphoprotein PEA-15", July 23, 1996 | |
| | AN | GenBank Accession No. P16157: "Ankyrin 1 (Erythrocyte Ankyrin)", April 1, 1990 | |
| | AO | GenBank Accession No. P08138: "Low-affinity nerve growth factor receptor precursor (NGF receptor)", Augsut 1, 1988 | |
| | AP | GenBank Accession No. P19438: "Tumor necrosis factor receptor 1 precursor (Tumor-necrosis factor binding protein 1)", February 1, 1991 | |
| | AQ | GenBank Accession No. NP_002459: "Myeloid differentiation primary response gene (88)", March 19, 1999 | |
| | AR | GenBank Accession No. P22366: "Myeloid/differentiation primary response protein MYD88", August 1, 1991 | |
| | AS | GenBank Accession No. P35445: "FASL Receptor precursor (apoptosis-mediating surface antigen FAS) (APO-1 Antigen) (CD95 Antigen)", May 1, 1992 | |
| | AT | GenBank Accession No. P53355: "Death-associated protein kinase 1 (DAP kinase 1)", October 1, 1996 | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number

Filing Date

First Named Inventor

David WALLACH

Group Art Unit

1642

Examiner Name

Attorney Docket Number

WALLACH=16A

19903 U.S. PTO
09/824134

04/03/01

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|----------------------|--------------------------------------|--|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Number | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|--------------------------|-----------------------|----------|--------------------------------------|--|--|---|----------------|
| | | Office ³ | Number | Kind Code ⁵ (if known) | | | | |
| | AA | WO | 96/12735 | A1 | Schievella | 05-02-1996 | | |
| | AB | WO | 96/30404 | A1 | Goeddell | 10-03-1996 | | |
| | AC | WO | 96/31603 | A2 | Dixit et al | 10-10-1996 | | |
| | AD | WO | 96/36730 | A1 | Leder et al | 11-21-1996 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|-----------------------|--------------------------|--|----------------|
| | AE | BAKER et al, "Transducers of life and death: TNF receptor superfamily and associated proteins", <u>Oncogene</u> 12(1):1-9 91996) | |
| | AF | BOLDIN et al, "A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain", <u>J Biol Chem</u> 270(14):7795-7798 (1995) | |
| | AG | CHINNAIYAN et al, "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiated apoptosis", <u>Cell</u> 81:505-512 (1995) | |
| | AH | CLEMENT et al, "Fas and Tumor Necrosis Factor Receptor Mediated Cell Death: Similarities and Distinctions", <u>J Exp Med</u> 180:557-567 (1994) | |

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.